Research graph
References from Frequency and Clinical Correlates of Sarcopenia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Local targets link to admitted publications; unresolved targets remain external evidence.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1016/j.jhep.2023.06.003 · 2023 · External reference
EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.jhep.2024.04.031 · 2024 · External reference
Metabolic dysfunction-associated steatotic liver disease in adults: a review
10.1001/jama.2025.19615 · 2026 · External reference
Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: a critical review of diagnostic, mechanistic, and therapeutic intersections
10.3748/wjg.v31.i31.110481 · 2025 · External reference
The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
10.1016/j.clnu.2024.07.006 · 2024 · External reference
Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis
10.1016/j.cgh.2023.02.013 · 2023 · External reference
Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study
10.1038/s41387-023-00250-6 · 2023 · External reference
Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression
10.1016/j.cgh.2022.01.020 · 2023 · External reference
Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
10.1186/s12937-025-01081-0 · 2025 · External reference
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
10.1016/j.jhep.2016.12.022 · 2017 · External reference
EASL clinical practice guidelines for the management of patients with decompensated cirrhosis
10.1016/j.jhep.2018.03.024 · 2018 · External reference
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
10.1016/j.kint.2023.10.018 · 2024 · External reference
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines
10.1161/cir.0000000000001063 · 2022 · External reference
Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease
10.1111/liv.14719 · 2021 · External reference
Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment
10.1016/j.jamda.2019.12.012 · 2020 · External reference
SARC-F: a simple questionnaire to rapidly diagnose sarcopenia
10.1016/j.jamda.2013.05.018 · 2013 · External reference
Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease
10.1002/jcsm.12754 · 2021 · External reference
The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
10.1186/s12876-024-03192-0 · 2024 · External reference
The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population
10.1002/jcsm.13099 · 2022 · External reference
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: a nationwide study
10.1111/jgh.16261 · 2023 · External reference
Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease
10.1016/j.cgh.2021.12.043 · 2023 · External reference
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
10.1016/j.jhepr.2020.100171 · 2020 · External reference
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
10.1016/j.jhep.2016.08.019 · 2017 · External reference
Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease
10.1002/jcsm.13351 · 2023 · External reference
Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease
10.1016/j.cgh.2022.11.031 · 2023 · External reference
Metabolic dysfunction-associated steatotic liver disease in adults: a review
10.1001/jama.2025.19615 · ExternalCitation · doi-reference
Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease
10.1002/jcsm.12754 · ExternalCitation · doi-reference
The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population
10.1002/jcsm.13099 · ExternalCitation · doi-reference
Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease
10.1002/jcsm.13351 · ExternalCitation · doi-reference
Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease
10.1016/j.cgh.2021.12.043 · ExternalCitation · doi-reference
Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression
10.1016/j.cgh.2022.01.020 · ExternalCitation · doi-reference
Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease
10.1016/j.cgh.2022.11.031 · ExternalCitation · doi-reference
Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis
10.1016/j.cgh.2023.02.013 · ExternalCitation · doi-reference
The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
10.1016/j.clnu.2024.07.006 · ExternalCitation · doi-reference
SARC-F: a simple questionnaire to rapidly diagnose sarcopenia
10.1016/j.jamda.2013.05.018 · ExternalCitation · doi-reference
Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment
10.1016/j.jamda.2019.12.012 · ExternalCitation · doi-reference
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
10.1016/j.jhep.2016.08.019 · ExternalCitation · doi-reference
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
10.1016/j.jhep.2016.12.022 · ExternalCitation · doi-reference
EASL clinical practice guidelines for the management of patients with decompensated cirrhosis
10.1016/j.jhep.2018.03.024 · ExternalCitation · doi-reference
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1016/j.jhep.2023.06.003 · ExternalCitation · doi-reference
EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.jhep.2024.04.031 · ExternalCitation · doi-reference
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
10.1016/j.jhepr.2020.100171 · ExternalCitation · doi-reference
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
10.1016/j.kint.2023.10.018 · ExternalCitation · doi-reference
Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study
10.1038/s41387-023-00250-6 · ExternalCitation · doi-reference
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: a nationwide study
10.1111/jgh.16261 · ExternalCitation · doi-reference
Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease
10.1111/liv.14719 · ExternalCitation · doi-reference
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines
10.1161/cir.0000000000001063 · ExternalCitation · doi-reference
The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
10.1186/s12876-024-03192-0 · ExternalCitation · doi-reference
Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
10.1186/s12937-025-01081-0 · ExternalCitation · doi-reference
Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: a critical review of diagnostic, mechanistic, and therapeutic intersections
10.3748/wjg.v31.i31.110481 · ExternalCitation · doi-reference
